Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-0895-1
Abstract: IntroductionThe present interim report of the STELLA-LONG TERM study aimed to examine the safety and effectiveness of ipragliflozin in real-word clinical practice in Japan using data up to 12 months. We also evaluated the effect of… read more here.
Keywords: ipragliflozin; liver function; safety; study ... See more keywords
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Pharmacology"
DOI: 10.1016/j.ejphar.2017.11.020
Abstract: Abstract Obesity due to excessive calorie intake is a known aggravating factor contributing to the development and progression of type 2 diabetes. Recently, excessive intake of sugar‐sweetened beverages has presented challenges in stemming the tide… read more here.
Keywords: sugar solution; ipragliflozin; type diabetic; solution ... See more keywords
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Pharmacology"
DOI: 10.1016/j.ejphar.2018.04.024
Abstract: Abstract Diabetic nephropathy is the leading cause of end‐stage renal disease in the world. Although recent development of sodium‐glucose cotransporter (SGLT) 2 inhibitors offers a new antidiabetic therapeutic strategy, it remains unclear whether such treatments… read more here.
Keywords: ipragliflozin; sglt2 inhibitor; type diabetic; diabetic nephropathy ... See more keywords
Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents
Sign Up to like & getrecommendations! Published in 2018 at "Life Sciences"
DOI: 10.1016/j.lfs.2018.02.009
Abstract: Aims: Daily intake of carbohydrates differs among individual patients with type 2 diabetes. Here, we investigated whether or not dietary carbohydrate content affects the efficacy of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in type… read more here.
Keywords: ipragliflozin; sglt2 inhibitor; carbohydrate; diabetic mice ... See more keywords
Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine Research"
DOI: 10.1080/07435800.2020.1713802
Abstract: ABSTRACT Background and aim: Sodium-glucose cotransporter (SGLT) 2 is responsible for most of the glucose reabsorption in the kidneys and has been proposed as a novel therapeutic target for the treatment of type 2 diabetes.… read more here.
Keywords: ipragliflozin; metformin; type diabetic; type ... See more keywords
Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2016.1261110
Abstract: ABSTRACT Background: Chronic hyperglycemia has an adverse influence on beta-cell function, which is known as ‘glucotoxicity’. Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower the blood glucose concentration by enhancing urinary glucose excretion. This study was performed to… read more here.
Keywords: ipragliflozin; patients type; japanese patients; proinsulin peptide ... See more keywords
Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0261310
Abstract: Non-alcoholic steatohepatitis (NASH) is a common chronic liver disease with no decisive treatment. The sodium glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin was developed as a new oral hypoglycemic drug, which can improve NASH via an… read more here.
Keywords: development; ipragliflozin; non alcoholic; model ... See more keywords
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Sign Up to like & getrecommendations! Published in 2017 at "Diabetes Care"
DOI: 10.2337/dc17-0518
Abstract: OBJECTIVE To compare the efficacy of ipragliflozin versus pioglitazone in patients with type 2 diabetes complicated by nonalcoholic fatty liver disease (NAFLD). RESEARCH DESIGN AND METHODS In this open-label, randomized, active-controlled trial, we randomly assigned… read more here.
Keywords: ipragliflozin; patients type; week; pioglitazone ... See more keywords